Pheochromocytoma (PHEO) and paraganglioma (PGL) are rare neuroendocrine tumors derived from neural crest cells. Germline variants in approximately 20 PHEO/PGL susceptibility genes are found in about 40% of patients, half of which are found in the genes that encode succinate dehydrogenase (SDH). Patients with SDH subunit B (SDHB)-mutated PHEO/PGL exhibit a higher likelihood of developing metastatic disease, which can be partially explained by the metabolic cell reprogramming and redox imbalance caused by the mutation. Reactive oxygen species (ROS) are highly reactive molecules involved in a multitude of important signaling pathways. A moderate level of ROS production can help regulate cellular physiology; however, an excessive level of oxidative stress can lead to tumorigenic processes including stimulation of growth factor-dependent pathways and the induction of genetic instability. Tumor cells effectively exploit antioxidant enzymes in order to protect themselves against harmful intracellular ROS accumulation, which highlights the essential balance between ROS production and scavenging. Exploiting ROS accumulation can be used as a possible therapeutic strategy in ROS-scavenging tumor cells. Here, we focus on the role of ROS production in PHEO and PGL, predominantly in SDHB-mutated cases. We discuss potential strategies and approaches to anticancer therapies by enhancing ROS production in these difficult-to-treat tumors.

Institute of Biotechnology Czech Academy of Sciences BIOCEV Vestec 252 50 Prague West Czech Republic

Neuro Oncology Branch Center for Cancer Research National Cancer Institute National Institutes of Health Bethesda MD 20892 USA

School of Pharmacy and Medical Science Griffith University Southport QLD 4222 Australia

Section of Medical Neuroendocrinology Eunice Kennedy Shriver National Institute of Child Health and Human Development National Institutes of Health Bethesda MD 20892 USA

Zobrazit více v PubMed

Dröge W. Free radicals in the physiological control of cell function. Physiol. Rev. 2002;82:47–95. doi: 10.1152/physrev.00018.2001. PubMed DOI

Forman H.J., Ursini F., Maiorino M. An overview of mechanisms of redox signaling. J. Mol. Cell Cardiol. 2014;73:2–9. doi: 10.1016/j.yjmcc.2014.01.018. PubMed DOI PMC

Costa A., Scholer-Dahirel A., Mechta-Grigoriou F. The role of reactive oxygen species and metabolism on cancer cells and their microenvironment. Semin. Cancer Biol. 2014;25:23–32. doi: 10.1016/j.semcancer.2013.12.007. PubMed DOI

Nishikawa M. Reactive oxygen species in tumor metastasis. Cancer Lett. 2008;266:53–59. doi: 10.1016/j.canlet.2008.02.031. PubMed DOI

Schieber M., Chandel N.S. ROS Function in Redox Signaling and Oxidative Stress. Curr. Biol. 2014;24:R453–R462. doi: 10.1016/j.cub.2014.03.034. PubMed DOI PMC

Harris I.S., Treloar A.E., Inoue S., Sasaki M., Gorrini C., Lee K.C., Yung K.Y., Brenner D., Knobbe-Thomsen C.B., Cox M.A., et al. Glutathione and thioredoxin antioxidant pathways synergize to drive cancer initiation and progression. Cancer Cell. 2015;27:211–222. doi: 10.1016/j.ccell.2014.11.019. PubMed DOI

Panieri E., Santoro M.M. ROS homeostasis and metabolism: A dangerous liaison in cancer cells. Cell Death Dis. 2016;7:e2253. doi: 10.1038/cddis.2016.105. PubMed DOI PMC

Perillo B., Di Donato M., Pezone A., Di Zazzo E., Giovannelli P., Galasso G., Castoria G., Migliaccio A. ROS in cancer therapy: The bright side of the moon. Exp. Mol. Med. 2020;52:192–203. doi: 10.1038/s12276-020-0384-2. PubMed DOI PMC

Fishbein L., Leshchiner I., Walter V., Danilova L., Robertson A.G., Johnson A.R., Lichtenberg T.M., Murray B.A., Ghayee H.K., Else T., et al. Comprehensive Molecular Characterization of Pheochromocytoma and Paraganglioma. Cancer Cell. 2017;31:181–193. doi: 10.1016/j.ccell.2017.01.001. PubMed DOI PMC

Remacha L., Comino-Méndez I., Richter S., Contreras L., Currás-Freixes M., Pita G., Letón R., Galarreta A., Torres-Pérez R., Honrado E., et al. Targeted Exome Sequencing of Krebs Cycle Genes Reveals Candidate Cancer-Predisposing Mutations in Pheochromocytomas and Paragangliomas. Clin. Cancer Res. 2017;23:6315–6324. doi: 10.1158/1078-0432.CCR-16-2250. PubMed DOI

Liu Y., Yang C. Oncometabolites in Cancer: Current Understanding and Challenges. Cancer Res. 2021;81:2820–2823. doi: 10.1158/0008-5472.CAN-20-3730. PubMed DOI

Neumann H.P., Bausch B., McWhinney S.R., Bender B.U., Gimm O., Franke G., Schipper J., Klisch J., Altehoefer C., Zerres K., et al. Germ-line mutations in nonsyndromic pheochromocytoma. N. Engl. J. Med. 2002;346:1459–1466. doi: 10.1056/NEJMoa020152. PubMed DOI

Eijkelenkamp K., Osinga T.E., Links T.P., Van der Horst-Schrivers A.N.A. Clinical implications of the oncometabolite succinate in SDHx-mutation carriers. Clin. Genet. 2020;97:39–53. doi: 10.1111/cge.13553. PubMed DOI PMC

Neumann H.P., Pawlu C., Peczkowska M., Bausch B., McWhinney S.R., Muresan M., Buchta M., Franke G., Klisch J., Bley T.A., et al. Distinct clinical features of paraganglioma syndromes associated with SDHB and SDHD gene mutations. JAMA. 2004;292:943–951. doi: 10.1001/jama.292.8.943. PubMed DOI

Else T., Marvin M.L., Everett J.N., Gruber S.B., Arts H.A., Stoffel E.M., Auchus R.J., Raymond V.M. The clinical phenotype of SDHC-associated hereditary paraganglioma syndrome (PGL3) J. Clin. Endocrinol. Metab. 2014;99:E1482–E1486. doi: 10.1210/jc.2013-3853. PubMed DOI PMC

Amar L., Bertherat J., Baudin E., Ajzenberg C., Bressac-de Paillerets B., Chabre O., Chamontin B., Delemer B., Giraud S., Murat A., et al. Genetic testing in pheochromocytoma or functional paraganglioma. J. Clin. Oncol. 2005;23:8812–8818. doi: 10.1200/JCO.2005.03.1484. PubMed DOI

Heesterman B.L., Bayley J.P., Tops C.M., Hes F.J., Van Brussel B.T., Corssmit E.P., Hamming J.F., Van der Mey A.G., Jansen J.C. High prevalence of occult paragangliomas in asymptomatic carriers of SDHD and SDHB gene mutations. Eur. J. Hum. Genet. 2013;21:469–470. doi: 10.1038/ejhg.2012.203. PubMed DOI PMC

Van der Tuin K., Mensenkamp A.R., Tops C.M.J., Corssmit E.P.M., Dinjens W.N., Van de Horst-Schrivers A.N.A., Jansen J.C., De Jong M.M., Kunst H.P.M., Kusters B., et al. Clinical Aspects of SDHA-Related Pheochromocytoma and Paraganglioma: A Nationwide Study. J. Clin. Endocrinol. Metab. 2018;103:438–445. doi: 10.1210/jc.2017-01762. PubMed DOI

Ilanchezhian M., Jha A., Pacak K., Del Rivero J. Emerging Treatments for Advanced/Metastatic Pheochromocytoma and Paraganglioma. Curr. Treat. Options Oncol. 2020;21:85. doi: 10.1007/s11864-020-00787-z. PubMed DOI PMC

Hadrava Vanova K., Kraus M., Neuzil J., Rohlena J. Mitochondrial complex II and reactive oxygen species in disease and therapy. Redox Rep. 2020;25:26–32. doi: 10.1080/13510002.2020.1752002. PubMed DOI PMC

Moog S., Lussey-Lepoutre C., Favier J. Epigenetic and metabolic reprogramming of SDH-deficient paragangliomas. Endocr. Relat. Cancer. 2020;27:R451–R463. doi: 10.1530/ERC-20-0346. PubMed DOI

Lambert A.J., Brand M.D. Reactive oxygen species production by mitochondria. Methods Mol. Biol. 2009;554:165–181. doi: 10.1007/978-1-59745-521-3_11. PubMed DOI

Chouchani E.T., Pell V.R., Gaude E., Aksentijević D., Sundier S.Y., Robb E.L., Logan A., Nadtochiy S.M., Ord E.N.J., Smith A.C., et al. Ischaemic accumulation of succinate controls reperfusion injury through mitochondrial ROS. Nature. 2014;515:431–435. doi: 10.1038/nature13909. PubMed DOI PMC

Quinlan C.L., Orr A.L., Perevoshchikova I.V., Treberg J.R., Ackrell B.A., Brand M.D. Mitochondrial complex II can generate reactive oxygen species at high rates in both the forward and reverse reactions. J. Biol. Chem. 2012;287:27255–27264. doi: 10.1074/jbc.M112.374629. PubMed DOI PMC

Robb E.L., Hall A.R., Prime T.A., Eaton S., Szibor M., Viscomi C., James A.M., Murphy M.P. Control of mitochondrial superoxide production by reverse electron transport at complex I. J. Biol. Chem. 2018;293:9869–9879. doi: 10.1074/jbc.RA118.003647. PubMed DOI PMC

Lee S., Nakamura E., Yang H., Wei W., Linggi M.S., Sajan M.P., Farese R.V., Freeman R.S., Carter B.D., Kaelin W.G., et al. Neuronal apoptosis linked to EglN3 prolyl hydroxylase and familial pheochromocytoma genes: Developmental culling and cancer. Cancer Cell. 2005;8:155–167. doi: 10.1016/j.ccr.2005.06.015. PubMed DOI

Ishii T., Yasuda K., Akatsuka A., Hino O., Hartman P.S., Ishii N. A mutation in the SDHC gene of complex II increases oxidative stress, resulting in apoptosis and tumorigenesis. Cancer Res. 2005;65:203–209. PubMed

Slane B.G., Aykin-Burns N., Smith B.J., Kalen A.L., Goswami P.C., Domann F.E., Spitz D.R. Mutation of succinate dehydrogenase subunit C results in increased O2.-, oxidative stress, and genomic instability. Cancer Res. 2006;66:7615–7620. doi: 10.1158/0008-5472.CAN-06-0833. PubMed DOI

Dong L.F., Low P., Dyason J.C., Wang X.F., Prochazka L., Witting P.K., Freeman R., Swettenham E., Valis K., Liu J., et al. Alpha-tocopheryl succinate induces apoptosis by targeting ubiquinone-binding sites in mitochondrial respiratory complex II. Oncogene. 2008;27:4324–4335. doi: 10.1038/onc.2008.69. PubMed DOI PMC

Dong L.F., Freeman R., Liu J., Zobalova R., Marin-Hernandez A., Stantic M., Rohlena J., Valis K., Rodriguez-Enriquez S., Butcher B., et al. Suppression of tumor growth in vivo by the mitocan alpha-tocopheryl succinate requires respiratory complex II. Clin. Cancer Res. 2009;15:1593–1600. doi: 10.1158/1078-0432.CCR-08-2439. PubMed DOI

Owens K.M., Aykin-Burns N., Dayal D., Coleman M.C., Domann F.E., Spitz D.R. Genomic instability induced by mutant succinate dehydrogenase subunit D (SDHD) is mediated by O2(-•) and H2O2. Free Radic. Biol. Med. 2012;52:160–166. doi: 10.1016/j.freeradbiomed.2011.10.435. PubMed DOI PMC

Guzy R.D., Sharma B., Bell E., Chandel N.S., Schumacker P.T. Loss of the SdhB, but Not the SdhA, subunit of complex II triggers reactive oxygen species-dependent hypoxia-inducible factor activation and tumorigenesis. Mol. Cell Biol. 2008;28:718–731. doi: 10.1128/MCB.01338-07. PubMed DOI PMC

Saito Y., Ishii K.A., Aita Y., Ikeda T., Kawakami Y., Shimano H., Hara H., Takekoshi K. Loss of SDHB Elevates Catecholamine Synthesis and Secretion Depending on ROS Production and HIF Stabilization. Neurochem. Res. 2016;41:696–706. doi: 10.1007/s11064-015-1738-3. PubMed DOI

Liu Y., Pang Y., Zhu B., Uher O., Caisova V., Huynh T.T., Taieb D., Hadrava Vanova K., Ghayee H.K., Neuzil J., et al. Therapeutic Targeting of SDHB-Mutated Pheochromocytoma/Paraganglioma with Pharmacologic Ascorbic Acid. Clin. Cancer Res. 2020;26:3868–3880. doi: 10.1158/1078-0432.CCR-19-2335. PubMed DOI PMC

Liu Y., Pang Y., Caisova V., Ding J., Yu D., Zhou Y., Huynh T.T., Ghayee H., Pacak K., Yang C. Targeting NRF2-Governed Glutathione Synthesis for SDHB-Mutated Pheochromocytoma and Paraganglioma. Cancers. 2020;12 doi: 10.3390/cancers12020280. PubMed DOI PMC

Goncalves J., Moog S., Morin A., Gentric G., Müller S., Morrell A.P., Kluckova K., Stewart T.J., Andoniadou C.L., Lussey-Lepoutre C., et al. Loss of SDHB Promotes Dysregulated Iron Homeostasis, Oxidative Stress, and Sensitivity to Ascorbate. Cancer Res. 2021;81:3480–3494. doi: 10.1158/0008-5472.CAN-20-2936. PubMed DOI

Florio R., De Lellis L., Veschi S., Verginelli F., Di Giacomo V., Gallorini M., Perconti S., Sanna M., Mariani-Costantini R., Natale A., et al. Effects of dichloroacetate as single agent or in combination with GW6471 and metformin in paraganglioma cells. Sci. Rep. 2018;8:13610. doi: 10.1038/s41598-018-31797-5. PubMed DOI PMC

Pang Y., Lu Y., Caisova V., Liu Y., Bullova P., Huynh T.T., Zhou Y., Yu D., Frysak Z., Hartmann I., et al. Targeting NAD(+)/PARP DNA Repair Pathway as a Novel Therapeutic Approach to SDHB-Mutated Cluster I Pheochromocytoma and Paraganglioma. Clin. Cancer Res. 2018;24:3423–3432. doi: 10.1158/1078-0432.CCR-17-3406. PubMed DOI PMC

Helleday T., Petermann E., Lundin C., Hodgson B., Sharma R.A. DNA repair pathways as targets for cancer therapy. Nat. Rev. Cancer. 2008;8:193–204. doi: 10.1038/nrc2342. PubMed DOI

Hou D., Liu Z., Xu X., Liu Q., Zhang X., Kong B., Wei J.-J., Gong Y., Shao C. Increased oxidative stress mediates the antitumor effect of PARP inhibition in ovarian cancer. Redox Biol. 2018;17:99–111. doi: 10.1016/j.redox.2018.03.016. PubMed DOI PMC

Okon I.S., Zou M.-H. Mitochondrial ROS and cancer drug resistance: Implications for therapy. Pharm. Res. 2015;100:170–174. doi: 10.1016/j.phrs.2015.06.013. PubMed DOI PMC

Bhardwaj V., He J. Reactive Oxygen Species, Metabolic Plasticity, and Drug Resistance in Cancer. Int. J. Mol. Sci. 2020;21:3412. doi: 10.3390/ijms21103412. PubMed DOI PMC

Ichikawa Y., Ghanefar M., Bayeva M., Wu R., Khechaduri A., Naga Prasad S.V., Mutharasan R.K., Naik T.J., Ardehali H. Cardiotoxicity of doxorubicin is mediated through mitochondrial iron accumulation. J. Clin. Investig. 2014;124:617–630. doi: 10.1172/JCI72931. PubMed DOI PMC

Martiniova L., Lai E.W., Elkahloun A.G., Abu-Asab M., Wickremasinghe A., Solis D.C., Perera S.M., Huynh T.T., Lubensky I.A., Tischler A.S., et al. Characterization of an animal model of aggressive metastatic pheochromocytoma linked to a specific gene signature. Clin. Exp. Metastasis. 2009;26:239–250. doi: 10.1007/s10585-009-9236-0. PubMed DOI PMC

Fliedner S.M.J., Kaludercic N., Jiang X.-S., Hansikova H., Hajkova Z., Sladkova J., Limpuangthip A., Backlund P.S., Wesley R., Martiniova L., et al. Warburg Effect’s Manifestation in Aggressive Pheochromocytomas and Paragangliomas: Insights from a Mouse Cell Model Applied to Human Tumor Tissue. PLoS ONE. 2012;7:e40949. doi: 10.1371/journal.pone.0040949. PubMed DOI PMC

Pang Y., Yang C., Schovanek J., Wang H., Bullova P., Caisova V., Gupta G., Wolf K.I., Semenza G.L., Zhuang Z., et al. Anthracyclines suppress pheochromocytoma cell characteristics, including metastasis, through inhibition of the hypoxia signaling pathway. Oncotarget. 2017;8:22313–22324. doi: 10.18632/oncotarget.16224. PubMed DOI PMC

Dixon S.J., Stockwell B.R. The role of iron and reactive oxygen species in cell death. Nat. Chem. Biol. 2014;10:9–17. doi: 10.1038/nchembio.1416. PubMed DOI

Paech F., Bouitbir J., Krähenbühl S. Hepatocellular Toxicity Associated with Tyrosine Kinase Inhibitors: Mitochondrial Damage and Inhibition of Glycolysis. Front. Pharm. 2017;8:367. doi: 10.3389/fphar.2017.00367. PubMed DOI PMC

Paech F., Mingard C., Grünig D., Abegg V.F., Bouitbir J., Krähenbühl S. Mechanisms of mitochondrial toxicity of the kinase inhibitors ponatinib, regorafenib and sorafenib in human hepatic HepG2 cells. Toxicology. 2018;395:34–44. doi: 10.1016/j.tox.2018.01.005. PubMed DOI

Park S.J., Park Y.J., Shin J.H., Kim E.S., Hwang J.J., Jin D.H., Kim J.C., Cho D.H. A receptor tyrosine kinase inhibitor, Tyrphostin A9 induces cancer cell death through Drp1 dependent mitochondria fragmentation. Biochem. Biophys. Res. Commun. 2011;408:465–470. doi: 10.1016/j.bbrc.2011.04.053. PubMed DOI

Will Y., Dykens J.A., Nadanaciva S., Hirakawa B., Jamieson J., Marroquin L.D., Hynes J., Patyna S., Jessen B.A. Effect of the Multitargeted Tyrosine Kinase Inhibitors Imatinib, Dasatinib, Sunitinib, and Sorafenib on Mitochondrial Function in Isolated Rat Heart Mitochondria and H9c2 Cells. Toxicol. Sci. 2008;106:153–161. doi: 10.1093/toxsci/kfn157. PubMed DOI

Rodríguez-Hernández M.A., De la Cruz-Ojeda P., López-Grueso M.J., Navarro-Villarán E., Requejo-Aguilar R., Castejón-Vega B., Negrete M., Gallego P., Vega-Ochoa Á., Victor V.M., et al. Integrated molecular signaling involving mitochondrial dysfunction and alteration of cell metabolism induced by tyrosine kinase inhibitors in cancer. Redox Biol. 2020;36:101510. doi: 10.1016/j.redox.2020.101510. PubMed DOI PMC

Almeida M.Q., Bezerra-Neto J.E., Mendonça B.B., Latronico A.C., Fragoso M.C.B.V. Primary malignant tumors of the adrenal glands. Clinics. 2018;73:e756s. doi: 10.6061/clinics/2018/e756s. PubMed DOI PMC

Ayala-Ramirez M., Chougnet C.N., Habra M.A., Palmer J.L., Leboulleux S., Cabanillas M.E., Caramella C., Anderson P., Al Ghuzlan A., Waguespack S.G., et al. Treatment with sunitinib for patients with progressive metastatic pheochromocytomas and sympathetic paragangliomas. J. Clin. Endocrinol. Metab. 2012;97:4040–4050. doi: 10.1210/jc.2012-2356. PubMed DOI PMC

Warkad M.S., Kim C.H., Kang B.G., Park S.H., Jung J.S., Feng J.H., Inci G., Kim S.C., Suh H.W., Lim S.S., et al. Metformin-induced ROS upregulation as amplified by apigenin causes profound anticancer activity while sparing normal cells. Sci. Rep. 2021;11:14002. doi: 10.1038/s41598-021-93270-0. PubMed DOI PMC

Li B., Zhou P., Xu K., Chen T., Jiao J., Wei H., Yang X., Xu W., Wan W., Xiao J. Metformin induces cell cycle arrest, apoptosis and autophagy through ROS/JNK signaling pathway in human osteosarcoma. Int. J. Biol. Sci. 2020;16:74–84. doi: 10.7150/ijbs.33787. PubMed DOI PMC

Wang L., Duan Q., Wang T., Ahmed M., Zhang N., Li Y., Li L., Yao X. Mitochondrial Respiratory Chain Inhibitors Involved in ROS Production Induced by Acute High Concentrations of Iodide and the Effects of SOD as a Protective Factor. Oxid. Med. Cell Longev. 2015;2015:217670. doi: 10.1155/2015/217670. PubMed DOI PMC

Mogavero A., Maiorana M.V., Zanutto S., Varinelli L., Bozzi F., Belfiore A., Volpi C.C., Gloghini A., Pierotti M.A., Gariboldi M. Metformin transiently inhibits colorectal cancer cell proliferation as a result of either AMPK activation or increased ROS production. Sci. Rep. 2017;7:15992. doi: 10.1038/s41598-017-16149-z. PubMed DOI PMC

Wheaton W.W., Weinberg S.E., Hamanaka R.B., Soberanes S., Sullivan L.B., Anso E., Glasauer A., Dufour E., Mutlu G.M., Budigner G.S., et al. Metformin inhibits mitochondrial complex I of cancer cells to reduce tumorigenesis. eLife. 2014;3:e02242. doi: 10.7554/eLife.02242. PubMed DOI PMC

Park W.H., Han Y.W., Kim S.H., Kim S.Z. An ROS generator, antimycin A, inhibits the growth of HeLa cells via apoptosis. J. Cell Biochem. 2007;102:98–109. doi: 10.1002/jcb.21280. PubMed DOI

Park D. Metformin Induces Oxidative Stress-Mediated Apoptosis without the Blockade of Glycolysis in H4IIE Hepatocellular Carcinoma Cells. Biol. Pharm. Bull. 2019;42:2002–2008. doi: 10.1248/bpb.b19-00474. PubMed DOI

Li M., Jiang X., Su T., Jiang L., Zhou W., Wang W. Metformin Suppresses Proliferation and Viability of Rat Pheochromocytoma Cells. Med. Sci. Monit. 2017;23:3253–3260. doi: 10.12659/MSM.903348. PubMed DOI PMC

Thakur S., Daley B., Klubo-Gwiezdzinska J. The role of an anti-diabetic drug metformin in the treatment of endocrine tumors. J. Mol. Endocrinol. 2019;63:R17–R35. doi: 10.1530/JME-19-0083. PubMed DOI PMC

Zhou Q., Liu C., Liu W., Zhang H., Zhang R., Liu J., Zhang J., Xu C., Liu L., Huang S., et al. Rotenone Induction of Hydrogen Peroxide Inhibits mTOR-mediated S6K1 and 4E-BP1/eIF4E Pathways, Leading to Neuronal Apoptosis. Toxicol. Sci. 2015;143:81–96. doi: 10.1093/toxsci/kfu211. PubMed DOI PMC

Liu Y., Lang F., Yang C. NRF2 in human neoplasm: Cancer biology and potential therapeutic target. Pharm. Ther. 2021;217:107664. doi: 10.1016/j.pharmthera.2020.107664. PubMed DOI

Hempel N., Carrico P.M., Melendez J.A. Manganese superoxide dismutase (Sod2) and redox-control of signaling events that drive metastasis. Anticancer. Agents Med. Chem. 2011;11:191–201. doi: 10.2174/187152011795255911. PubMed DOI PMC